Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1993 Sep;31(9):2320–2326. doi: 10.1128/jcm.31.9.2320-2326.1993

Genome macrorestriction analysis of diversity and variability of Pseudomonas aeruginosa strains infecting cystic fibrosis patients.

M J Struelens 1, V Schwam 1, A Deplano 1, D Baran 1
PMCID: PMC265754  PMID: 8408549

Abstract

Genome macrorestriction fingerprinting with XbaI and DraI was used to analyze the relatedness of 166 Pseudomonas aeruginosa isolates collected from 31 cystic fibrosis patients over a 1- to 20-month period and to correlate their genotype with patterns of resistance to 14 antimicrobial agents. Quantitative comparison of intra- and interpatient similarities of P. aeruginosa macrorestriction patterns disclosed two discrete ranges that clearly discriminated subclonal variation (> 80% relatedness) and clonal diversity (10 to 70% relatedness). Cloning-derived mutants exhibited up to 20% divergence of genomic macrorestriction patterns during the course of chronic colonization of individual patients. Change of susceptibility to multiple antimicrobial agents developed in 50% of sequential pairs of isolates from individual patients. Only 19% of these susceptibility changes were attributable to strain substitution, while the majority (56%) of resistance changes were associated with minor genomic variations of a persistent strain. Sixty-six percent of patients harbored one strain, and 33% carried two strains. Three common strains colonized 5 (28%) of 18 patients attending a cystic fibrosis clinic, and another two strains colonized two patient pairs (31%) of 13 patients staying at a rehabilitation center, suggesting potential cross-infection in these settings. By indexing regional polymorphisms throughout the chromosome structure, macrorestriction analysis can monitor subclonal evolution of P. aeruginosa and identify isogenic resistance mutants. Quantitative macrorestriction fingerprinting enables discrimination between clonal variants and clones of distinct origins and should therefore provide a reliable tool for investigating the mode of acquisition of P. aeruginosa in cystic fibrosis patients.

Full text

PDF
2320

Images in this article

2323Image
on p.2323
2324Image
on p.2324

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bryan L. E. Two forms of antimicrobial resistance: bacterial persistence and positive function resistance. J Antimicrob Chemother. 1989 Jun;23(6):817–820. doi: 10.1093/jac/23.6.817. [DOI] [PubMed] [Google Scholar]
  2. Chamberland S., Malouin F., Rabin H. R., Schollaardt T., Parr T. R., Jr, Bryan L. E. Persistence of Pseudomonas aeruginosa during ciprofloxacin therapy of a cystic fibrosis patient: transient resistance to quinolones and protein F-deficiency. J Antimicrob Chemother. 1990 Jun;25(6):995–1010. doi: 10.1093/jac/25.6.995. [DOI] [PubMed] [Google Scholar]
  3. Diver J. M., Schollaardt T., Rabin H. R., Thorson C., Bryan L. E. Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy. Antimicrob Agents Chemother. 1991 Aug;35(8):1538–1546. doi: 10.1128/aac.35.8.1538. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Giwercman B., Lambert P. A., Rosdahl V. T., Shand G. H., Høiby N. Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed beta-lactamase producing strains. J Antimicrob Chemother. 1990 Aug;26(2):247–259. doi: 10.1093/jac/26.2.247. [DOI] [PubMed] [Google Scholar]
  5. Hjelm L. N., Branstrom A. A., Warren R. L. Detection of restriction fragment length polymorphisms in clinical isolates and serially passaged Pseudomonas aeruginosa strains. J Clin Microbiol. 1990 Oct;28(10):2178–2182. doi: 10.1128/jcm.28.10.2178-2182.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kelly N. M., Fitzgerald M. X., Tempany E., O'Boyle C., Falkiner F. R., Keane C. T. Does pseudomonas cross-infection occur between cystic-fibrosis patients. Lancet. 1982 Sep 25;2(8300):688–690. doi: 10.1016/s0140-6736(82)90714-0. [DOI] [PubMed] [Google Scholar]
  7. McNeill W. F., John J. F., Jr, Twitty J. A. Aminoglycoside resistance in Pseudomonas aeruginosa isolated from cystic fibrosis patients. Am J Clin Pathol. 1984 Jun;81(6):742–747. doi: 10.1093/ajcp/81.6.742. [DOI] [PubMed] [Google Scholar]
  8. Ogle J. W., Janda J. M., Woods D. E., Vasil M. L. Characterization and use of a DNA probe as an epidemiological marker for Pseudomonas aeruginosa. J Infect Dis. 1987 Jan;155(1):119–126. doi: 10.1093/infdis/155.1.119. [DOI] [PubMed] [Google Scholar]
  9. Ogle J. W., Reller L. B., Vasil M. L. Development of resistance in Pseudomonas aeruginosa to imipenem, norfloxacin, and ciprofloxacin during therapy: proof provided by typing with a DNA probe. J Infect Dis. 1988 Apr;157(4):743–748. doi: 10.1093/infdis/157.4.743. [DOI] [PubMed] [Google Scholar]
  10. Ojeniyi B., Høiby N. Comparison of different typing methods of Pseudomonas aeruginosa. Antibiot Chemother (1971) 1991;44:13–22. doi: 10.1159/000420292. [DOI] [PubMed] [Google Scholar]
  11. Pasloske B. L., Joffe A. M., Sun Q., Volpel K., Paranchych W., Eftekhar F., Speert D. P. Serial isolates of Pseudomonas aeruginosa from a cystic fibrosis patient have identical pilin sequences. Infect Immun. 1988 Mar;56(3):665–672. doi: 10.1128/iai.56.3.665-672.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pedersen S. S., Koch C., Høiby N., Rosendal K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother. 1986 Apr;17(4):505–516. doi: 10.1093/jac/17.4.505. [DOI] [PubMed] [Google Scholar]
  13. Pitt T. L. Epidemiological typing of Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 1988 Apr;7(2):238–247. doi: 10.1007/BF01963095. [DOI] [PubMed] [Google Scholar]
  14. Portnoy D. A., Moseley S. L., Falkow S. Characterization of plasmids and plasmid-associated determinants of Yersinia enterocolitica pathogenesis. Infect Immun. 1981 Feb;31(2):775–782. doi: 10.1128/iai.31.2.775-782.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Speert D. P., Campbell M. E., Farmer S. W., Volpel K., Joffe A. M., Paranchych W. Use of a pilin gene probe to study molecular epidemiology of Pseudomonas aeruginosa. J Clin Microbiol. 1989 Nov;27(11):2589–2593. doi: 10.1128/jcm.27.11.2589-2593.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Speert D. P., Lawton D., Damm S. Communicability of Pseudomonas aeruginosa in a cystic fibrosis summer camp. J Pediatr. 1982 Aug;101(2):227–228. doi: 10.1016/s0022-3476(82)80127-3. [DOI] [PubMed] [Google Scholar]
  17. Thomassen M. J., Demko C. A., Boxerbaum B., Stern R. C., Kuchenbrod P. J. Multiple of isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis. J Infect Dis. 1979 Dec;140(6):873–880. doi: 10.1093/infdis/140.6.873. [DOI] [PubMed] [Google Scholar]
  18. Tümmler B., Koopmann U., Grothues D., Weissbrodt H., Steinkamp G., von der Hardt H. Nosocomial acquisition of Pseudomonas aeruginosa by cystic fibrosis patients. J Clin Microbiol. 1991 Jun;29(6):1265–1267. doi: 10.1128/jcm.29.6.1265-1267.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Wolz C., Kiosz G., Ogle J. W., Vasil M. L., Schaad U., Botzenhart K., Döring G. Pseudomonas aeruginosa cross-colonization and persistence in patients with cystic fibrosis. Use of a DNA probe. Epidemiol Infect. 1989 Apr;102(2):205–214. doi: 10.1017/s0950268800029873. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES